GeneDx Holdings Corp. Warrant

GeneDX CEO Katherine Stueland sold 2,158 shares on October 29, 2025, primarily to cover tax obligations after converting restricted stock units. The transaction was part of routine accounting and does not indicate a loss of confidence in the company.

Multiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.

Rosen Law Firm is investigating potential securities claims against GeneDx Holdings Corp. after a Grizzly Research report alleged widespread fraud, causing the stock to drop 6.7%.

GeneDx, a leader in genome and exome testing, saw its stock price surge over 2,700% in 2024. The company's strong earnings and revenue growth in Q4 2024 have continued into 2025, with the stock price spiking 47% on Tuesday. However, a recent negative report by Grizzly Research has raised concerns about the company's growth.